부산대학교 도서관

The efficacy of rikkunshito (TJ-43) is reported as antiemesis method of treatment to chemotherapy induced nausea and vomiting (CINV) associated with platinum based chemotherapy. We experienced 3 cases of rikkunshito use as antiemetic in the radiotherapy (RT) concominant with temozolomide (TMZ) for treatment of gliomas. [Methods] All patients had taken ramosetron 0.1 mg before taking TMZ for prevention of CINV. Metclopramide 5 mg had been administrated as needed. If patient had still complianed of continuous nausea, rikkunshito (2.5 g of rikkunshito three times a day before each meal) were added. The change of the nausea and dietary intake was evaluated retrospectively. [Result] The administration of rikkunshito suppressed the nausea in two of 3 cases, and their dietary intake rates were improved. [Conclusion] This is the first report that rikkunshito may alleviate the delayed emesis and loss of appetite associated with TMZ and RT.